Quince Therapeutics, Inc. (QNCX) Investor Relations Documents

Quince Therapeutics, Inc. (QNCX) investor relations documents from the company's IR site: 14 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-14Press releasePDF Version
2026-08-14Press releaseQuince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
2026-06-30Press releaseQuince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
2026-05-18Press releaseQuince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures i
2026-05-18Press releaseQuince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
2026-03-30Press releaseQuince Therapeutics Settles Approximately $16.4 Million of Debt
2026-02-09Press releaseQuince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
2026-01-29Press releaseQuince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
2026-01-28Press releaseQuince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British
2020-03-16Press releasePDF Version
2020-02-13Press releasePDF Version
2020-01-30Press releasePDF Version
2020-01-13Press releasePDF Version
2020-01-08Press releasePDF Version

QNCX overview · QNCX earnings · QNCX financials · QNCX KPIs · QNCX ownership · QNCX peers · QNCX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.